Aclaris Therapeutics Inc expected to post a loss of 1 cent a share - Earnings Preview

Aclaris Therapeutics

01/11/2024 14:57

* Aclaris Therapeutics Inc  ACRS.OQ   ACRS.O  is expected
to show
a fall in quarterly revenue when it reports  results on November
4 (estimated) for the period ending September 30 2024
    * The Wayne Pennsylvania-based  company is expected to
report a
23.3% decrease in revenue to $7.119 million from $9.28 million a
year ago, according to the mean estimate from 5 analysts, based
on LSEG data.
    * ​LSEG's mean analyst estimate for Aclaris Therapeutics Inc
is
for a loss of 1 cent per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 7
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Aclaris
Therapeutics Inc is $1.60​, below​ its last closing price
of $1.81. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -0.20       -0.20      -0.15     Beat    26.6
 Mar. 31 2024  -0.26       -0.29      -0.24     Beat    16
 Dec. 31 2023  -0.33       -0.34      -0.02     Beat    94.2​
 Sep. 30 2023  -0.47       -0.48      -0.41     Beat    14.6
 ​​Jun.        -0.44       -0.45      -0.42     Beat    6.7
 30 2023                                                
 Mar. 31 2023  -0.43       -0.44      -0.40     Beat    8.6​
 Dec. 31 2022  -0.45       -0.45      -0.41     Beat    8
 Sep. 30 2022  -0.39       -0.40      -0.30     Beat    24.2
 This summary was machine generated November 1 at 14:57 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)